{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7137,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": "https://imgproxy.kitesheet.com/9SJ4fBlSyXwB7ReAYr2dYBo2Vwh6n9pVSJA17skn1CA/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MTBlODM1NWMzYjEyNGIwNjJhNDQ5ZDZiMzg0OGJhOS9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/1",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 1,
          "beatId": "c782c61d-73a9-406f-a0bd-432431ac0857",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "Introduction to Immix Biopharma and its focus on oncology and immunology",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": "https://imgproxy.kitesheet.com/XA4utuTkfOBH4MwEtJhmfVp5cCFW3qK7CKduG67iz38/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MTBlODM1NWMzYjEyNGIwNjJhNDQ5ZDZiMzg0OGJhOS9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/7_W1NxoTAyorELjegNzZgr4vz78lWpkc3ZMrvYLcZd8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MTBlODM1NWMzYjEyNGIwNjJhNDQ5ZDZiMzg0OGJhOS9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/vFE6JKcZZPEcygABMsVdPqyFeelgsFi95SnCKTK5W8Q/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MTBlODM1NWMzYjEyNGIwNjJhNDQ5ZDZiMzg0OGJhOS9wMDAxLnBuZw"
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "disclaimer",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/2",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 1,
          "beatId": "c782c61d-73a9-406f-a0bd-432431ac0857",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "Introduction to Immix Biopharma and its focus on oncology and immunology",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": "The slide uses a numbered list format to present key value propositions.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/3",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 1,
          "beatId": "c782c61d-73a9-406f-a0bd-432431ac0857",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "Introduction to Immix Biopharma and its focus on oncology and immunology",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": "The slide highlights two distinct pipelines: N-GENIUS (cell therapy) and SMARxT (tissue-specific).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/4",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 1,
          "beatId": "c782c61d-73a9-406f-a0bd-432431ac0857",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "Introduction to Immix Biopharma and its focus on oncology and immunology",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a stylized area chart to represent market segments and their associated financial opportunities.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/5",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-5",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 7,
          "from": 5,
          "beatId": "4b86493a-1393-464b-b6ad-158ad0028028",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Problem & Complication",
          "beatSlug": "consultants-gambit-problem-complication",
          "evidence": "Discussion of current problems with BCMA CAR-T therapies",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "roadmap",
      "function": "show_traction",
      "notes": "The table uses a standard pharmaceutical pipeline layout with clinical and preclinical segments.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/6",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-6",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 7,
          "from": 5,
          "beatId": "4b86493a-1393-464b-b6ad-158ad0028028",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Problem & Complication",
          "beatSlug": "consultants-gambit-problem-complication",
          "evidence": "Discussion of current problems with BCMA CAR-T therapies",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The slide uses a hub-and-spoke diagram to illustrate the negative consequences of neurotoxicity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/7",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-7",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 7,
          "from": 5,
          "beatId": "4b86493a-1393-464b-b6ad-158ad0028028",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Problem & Complication",
          "beatSlug": "consultants-gambit-problem-complication",
          "evidence": "Discussion of current problems with BCMA CAR-T therapies",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes a cartoon liver character, likely representing the target organ or safety profile.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/8",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-8",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "Includes extensive disclaimer text regarding cross-trial comparison limitations.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/9",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-9",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "Includes detailed source citations in the footer.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/10",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-10",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "Includes detailed source citations in the footer; uses a color-coded legend for different drug treatments.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/11",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-11",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a two-column layout to separate milestones by drug candidate.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/12",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-12",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "solution",
      "function": "present_solution",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/13",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-13",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/14",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-14",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
      "docSlug": "810e8355c3b124b062a449d6b3848ba9",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a table structure to contrast clinical outcomes across three key value pillars: response rates, tolerability, and outpatient feasibility.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/15",
      "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
      "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-15",
      "loopMatches": [
        {
          "to": 21,
          "from": 7,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
          "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
          "position": 0,
          "objective": "Highlighting the need for improved therapies",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 21,
          "from": 8,
          "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 38,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a process flow diagram to show the progression of clinical trials for two different treatment regimens.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/38",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-38",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 39,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/39",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-39",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 40,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a process-flow style layout to connect platform capabilities to specific clinical assets.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/40",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-40",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 41,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a 3-pillar framework to explain the platform, followed by a product-specific breakdown.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/41",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-41",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 42,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes technical diagrams of the drug construct, comparative histology, and survival curves.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/42",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-42",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 43,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Includes two sets of charts: tumor volume line graphs and survival curves. References specific study methodology in footnotes.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/43",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-43",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 44,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a two-part structure: clinical efficacy (top right) and mechanism of action (bottom right).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/44",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-44",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 45,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/45",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-45",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 48,
          "from": 45,
          "beatId": "b5cbc254-61b1-4167-96e7-f66088f734e8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Team",
          "beatSlug": "sequoia-pitch-team",
          "evidence": "Introduction to Immix Biopharma's team",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 46,
      "slideType": "team_bio",
      "function": "other",
      "notes": "The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Select Nexcella Scientific Advisory Board Members (bottom).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/46",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-46",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 48,
          "from": 45,
          "beatId": "b5cbc254-61b1-4167-96e7-f66088f734e8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Team",
          "beatSlug": "sequoia-pitch-team",
          "evidence": "Introduction to Immix Biopharma's team",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 47,
      "slideType": "team_bio",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/47",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-47",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 48,
          "from": 45,
          "beatId": "b5cbc254-61b1-4167-96e7-f66088f734e8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Team",
          "beatSlug": "sequoia-pitch-team",
          "evidence": "Introduction to Immix Biopharma's team",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 48,
      "slideType": "team_bio",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/48",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-48",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 48,
          "from": 45,
          "beatId": "b5cbc254-61b1-4167-96e7-f66088f734e8",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Team",
          "beatSlug": "sequoia-pitch-team",
          "evidence": "Introduction to Immix Biopharma's team",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 49,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/49",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-49",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 50,
      "slideType": "appendix",
      "function": "appendix",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/50",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-50",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 51,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a bar chart to contrast the combined sales of two groups of drugs, illustrating the market size for specific oncology indications.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/51",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-51",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
      "docSlug": "63ec8e773c9b43e7b033b64167026114",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 52,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/52",
      "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
      "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-52",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}